BioCryst Pharmaceuticals, Inc

Biocryst Pharmaceuticals is a U.S.-based biotechnology company focused on rare diseases, with its core commercial product ORLADEYO for hereditary angioedema (HAE). The company combines internal drug discovery with business development to build a pipeline of oral small molecules and injectable protein therapeutics. It has built a commercial infrastructure around ORLADEYO and uses that platform to support additional rare-disease programs. Biocryst also earns collaborative, license, service, and royalty revenue from third-party agreements, making it both a commercial-stage biotech and a development-stage pipeline company.

39,1 %

97,8 %

30,2 %

+94,1 %

2.06

2.03

— BioCryst Pharmaceuticals, Inc
%
Commercial product sales80% Approved pharmaceutical products sold to specialty pharmacies, distributors, hospitals, and pharmacies, primarily ORLADEYO and peramivir.
Collaborative and license revenue15% License fees, milestone payments, service revenue, and royalties from third-party collaborations and out-licensing arrangements.
Pipeline development programs5% Internal discovery and clinical-stage rare-disease candidates that are not yet commercial products.

Biocryst sells primarily into the rare-disease treatment ecosystem rather than to broad retail consumers...

  • U.S. specialty pharmacy channelprimary

    Buys ORLADEYO for direct-to-patient dispensing in the U.S. and is central to prescription fulfillment and revenue recognition.

  • International distributors, hospitals, and pharmaciesprimary

    Purchase ORLADEYO outside the U.S. and support market access in ex-U.S. rare-disease markets.

  • Patients with hereditary angioedemaprimary

    The end users of ORLADEYO; demand depends on diagnosis, physician prescribing, adherence, and reimbursement.

  • Pharmaceutical collaboration partnerssecondary

    Pay for licenses, services, milestones, or royalties tied to partnered programs and out-licensed assets.

  • Healthcare providers and specialty prescriberssecondary

    Influence adoption of ORLADEYO and other rare-disease therapies through prescribing decisions.

Biocryst describes itself as a global biotechnology company, but its commercial base is anchored in the United States...

  • •United States is the core commercial market for ORLADEYO
  • •Ex-U.S. sales are routed through specialty distributors, hospitals, and pharmacies
  • •European ORLADEYO business is subject to a pending sale transaction
  • •Global operations depend on third-party manufacturers and partners
  • •Geographic mix matters because reimbursement and access differ by market

Biocryst’s strategy is to use ORLADEYO as the commercial anchor while expanding into additional rare-disease...

01
Expand ORLADEYO commercializationshort-term

ORLADEYO is the main revenue engine and supports the company’s commercial infrastructure.

02
Advance rare-disease pipeline programsmedium-term

Pipeline success is needed to diversify revenue beyond a single commercial product.

03
Use partnerships and monetization to fund growthmedium-term

Non-dilutive funding can extend runway and reduce dependence on capital markets.

Biocryst faces the classic risks of a commercial-stage rare-disease biotech: dependence on a small number of products,...

high

Dependence on ORLADEYO commercialization

The company’s revenue and commercial infrastructure are heavily tied to one core HAE product.

Scope
ORLADEYO sales, patient retention, and physician adoption
Materiality
high
high

Reimbursement and pricing pressure

Revenue from product sales depends on favorable pricing and third-party payor coverage.

Scope
U.S. specialty pharmacy channel and ex-U.S. market access
Materiality
high
high

Clinical and regulatory failure

Pipeline assets may not achieve approval or commercial viability, limiting future growth.

Scope
Rare-disease development programs
Materiality
high
high

Manufacturing and supply chain disruption

Biologics and pharmaceutical manufacturing are complex and rely on third parties.

Scope
Contract manufacturers, quality control, and product supply
Materiality
high
medium

Competitive pressure

Larger competitors may launch safer, more effective, or lower-cost alternatives.

Scope
HAE and other rare-disease markets
Materiality
high
Product sales reserves and non-acceptance estimates
Can shift revenue between quarters and affect gross-to-net visibility
Collaborative and license revenue recognition
Can create lumpy revenue patterns
Deferred tax asset valuation allowance
Affects reported tax expense and effective tax rate

BIOCRYST PHARMACEUTICALS INC

BCRX · Biological Products, (No Diagnostic Substances)

Cocrystal Pharma, Inc.

COCP · Pharmaceutical Preparations

BioCorRx Inc.

BICX · Services-Specialty Outpatient Facilities, NEC

Camurus

CAMX.ST · Health Care

Xeris Biopharma Holdings, Inc.

XERS · Pharmaceutical Preparations

Journey Medical Corp

DERM · Pharmaceutical Preparations

: 11/08/2026